ATE387910T1 - Verfahren zur verbesserung der bioverfügbarkeit von ospemifen - Google Patents

Verfahren zur verbesserung der bioverfügbarkeit von ospemifen

Info

Publication number
ATE387910T1
ATE387910T1 AT05701734T AT05701734T ATE387910T1 AT E387910 T1 ATE387910 T1 AT E387910T1 AT 05701734 T AT05701734 T AT 05701734T AT 05701734 T AT05701734 T AT 05701734T AT E387910 T1 ATE387910 T1 AT E387910T1
Authority
AT
Austria
Prior art keywords
bioavailability
ospemifene
improving
compound
stereoisomer
Prior art date
Application number
AT05701734T
Other languages
German (de)
English (en)
Inventor
Markku Anttila
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34837941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE387910(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Application granted granted Critical
Publication of ATE387910T1 publication Critical patent/ATE387910T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AT05701734T 2004-02-13 2005-01-14 Verfahren zur verbesserung der bioverfügbarkeit von ospemifen ATE387910T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/777,211 US8236861B2 (en) 2004-02-13 2004-02-13 Method for enhancing the bioavailablity of ospemifene

Publications (1)

Publication Number Publication Date
ATE387910T1 true ATE387910T1 (de) 2008-03-15

Family

ID=34837941

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05701734T ATE387910T1 (de) 2004-02-13 2005-01-14 Verfahren zur verbesserung der bioverfügbarkeit von ospemifen

Country Status (23)

Country Link
US (5) US8236861B2 (enEXAMPLES)
EP (1) EP1713458B1 (enEXAMPLES)
JP (2) JP5577011B2 (enEXAMPLES)
CN (1) CN1925847A (enEXAMPLES)
AT (1) ATE387910T1 (enEXAMPLES)
AU (1) AU2005211958B2 (enEXAMPLES)
BE (1) BE2015C033I2 (enEXAMPLES)
BR (1) BRPI0507661A (enEXAMPLES)
CA (1) CA2556089C (enEXAMPLES)
CY (2) CY1111014T1 (enEXAMPLES)
DE (1) DE602005005165T2 (enEXAMPLES)
DK (1) DK1713458T5 (enEXAMPLES)
ES (1) ES2302177T3 (enEXAMPLES)
FR (1) FR15C0041I2 (enEXAMPLES)
HU (1) HUS1500030I1 (enEXAMPLES)
LT (1) LTC1713458I2 (enEXAMPLES)
LU (1) LU92736I2 (enEXAMPLES)
MX (1) MXPA06009274A (enEXAMPLES)
NO (2) NO337656B1 (enEXAMPLES)
PL (1) PL1713458T3 (enEXAMPLES)
PT (1) PT1713458E (enEXAMPLES)
RU (1) RU2385716C2 (enEXAMPLES)
WO (1) WO2005077350A1 (enEXAMPLES)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236861B2 (en) * 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
PT2275098E (pt) 2004-05-04 2012-08-29 Hormos Medical Ltd Novas formulações orais de ospemifeno
CN101304738A (zh) * 2005-11-09 2008-11-12 霍尔莫斯医疗有限公司 非培米芬的制剂
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
EA023472B1 (ru) * 2005-11-28 2016-06-30 Джи Ти Икс, ИНК. Агенты, связывающиеся с ядерными рецепторами
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
US8546451B2 (en) 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
WO2008099060A2 (en) * 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
US7812197B2 (en) * 2007-02-14 2010-10-12 Hormos Medical Ltd. Method for the preparation of therapeutically valuable triphenylbutene derivatives
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9321712B2 (en) 2012-10-19 2016-04-26 Fermion Oy Process for the preparation of ospemifene
CN103739456A (zh) * 2013-12-03 2014-04-23 镇江圣安医药有限公司 2-（对-（（z-4-氯-1,2-二苯基-1-丁烯基）苯氧基）乙醇的新型衍生物及其应用
GR1009542B (el) 2018-04-25 2019-06-07 Φαρματεν Α.Β.Ε.Ε. Καψουλα μαλακης γελης που περιλαμβανει εναν εκλεκτικο ρυθμιστη οιστρογονικων υποδοχεων
HUE064326T2 (hu) 2018-05-11 2024-03-28 Xenon Pharmaceuticals Inc Eljárások a feszültség-kapuzott kálium-csatornanyitó biológiai elérhetõségének és expozíciójának növelésére
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
NZ787838A (en) 2019-11-08 2025-08-29 Xenon Pharmaceuticals Inc Methods of treating depressive disorders
MX2023009314A (es) 2021-02-09 2023-08-16 Xenon Pharmaceuticals Inc Apertura del canal de potasio dependiente de voltaje para usarse en el tratamiento de la anhedonia.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
GB9418067D0 (en) * 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
GB9604577D0 (en) 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
WO2000008001A1 (en) * 1998-08-07 2000-02-17 Chiron Corporation Substituted isoxazole as estrogen receptor modulators
US6219674B1 (en) 1999-11-24 2001-04-17 Classen Immunotherapies, Inc. System for creating and managing proprietary product data
US6245819B1 (en) 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
US6653639B1 (en) * 2000-10-17 2003-11-25 Nikon Corporation Chuck for mounting reticle to a reticle stage
EP1377912A4 (en) 2001-02-22 2007-11-14 Classen Immunotherapies Inc Improved computer algorithms and methods for enhancing product safety
FR2826811B1 (fr) 2001-06-27 2003-11-07 France Telecom Procede d'authentification cryptographique
DE60309465T2 (de) 2002-06-06 2007-08-30 Hormos Medical Ltd. Verfahren zur Hemmung oder Vorbeugung von urogenitaler Atrophie und deren Symptome bei Frauen
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US20050187302A1 (en) 2004-02-23 2005-08-25 Hormos Medical Corporation Method for treatment or prevention of osteoporosis in individuals with high bone turnover
US8642079B2 (en) 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US8758821B2 (en) 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
US20060293294A1 (en) 2004-09-03 2006-12-28 Hormos Medical Corporation Method for treatment or prevention of androgen deficiency
KR100665758B1 (ko) * 2005-09-15 2007-01-09 제일모직주식회사 반사방지성을 갖는 하드마스크 조성물

Also Published As

Publication number Publication date
LTPA2015023I1 (lt) 2015-08-25
LTC1713458I2 (lt) 2017-06-26
US20050182143A1 (en) 2005-08-18
RU2385716C2 (ru) 2010-04-10
DE602005005165T2 (de) 2009-04-30
CY2015027I2 (el) 2016-04-13
JP2007522190A (ja) 2007-08-09
EP1713458A1 (en) 2006-10-25
AU2005211958B2 (en) 2010-11-25
RU2006132719A (ru) 2008-03-20
JP2014141533A (ja) 2014-08-07
US9241915B2 (en) 2016-01-26
US20130324614A1 (en) 2013-12-05
US9855224B2 (en) 2018-01-02
BE2015C033I2 (enEXAMPLES) 2024-08-08
CY1111014T1 (el) 2015-06-11
JP6023119B2 (ja) 2016-11-09
US20140303259A1 (en) 2014-10-09
PT1713458E (pt) 2008-05-07
WO2005077350A1 (en) 2005-08-25
ES2302177T3 (es) 2008-07-01
NO339190B1 (no) 2016-11-14
NO20151603L (no) 2006-11-03
DK1713458T5 (da) 2008-09-29
BRPI0507661A (pt) 2007-07-17
CN1925847A (zh) 2007-03-07
MXPA06009274A (es) 2007-04-16
US8236861B2 (en) 2012-08-07
US8772353B2 (en) 2014-07-08
US20160101065A1 (en) 2016-04-14
CY2015027I1 (el) 2016-04-13
DE602005005165D1 (de) 2008-04-17
NO337656B1 (no) 2016-05-23
DK1713458T3 (da) 2008-07-07
LU92736I2 (fr) 2015-08-10
CA2556089C (en) 2013-04-02
FR15C0041I2 (fr) 2015-11-13
CA2556089A1 (en) 2005-08-25
EP1713458B1 (en) 2008-03-05
US8470890B2 (en) 2013-06-25
HUS1500030I1 (hu) 2015-08-28
JP5577011B2 (ja) 2014-08-20
PL1713458T3 (pl) 2008-08-29
US20120270952A1 (en) 2012-10-25
NO20063960L (no) 2006-11-03
FR15C0041I1 (enEXAMPLES) 2015-07-17
AU2005211958A1 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
HUS1500030I1 (hu) Eljárás az ospemifene biohasznosulásának javítására
NO341573B1 (no) Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen
ZA202006378B (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
ATE537136T1 (de) Neues verfahren zur herstellung von säurechloriden
EA201270046A1 (ru) Новые производные фенилимидазола в качестве ингибиторов фермента pde10a
EA201100795A1 (ru) Фармацевтическая композиция эффективного ингибитора всг для перорального введения
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
RS54123B1 (en) THERAPEUTIC COMBINATION CONTAINING DOLUTEGRAVIR, ABACAVIR AND LAMIVUDINE
EA200800147A1 (ru) Способ получения олмесартан медоксомила
GT200500354A (es) Metodo para preparar n-fenilpirazol-1-carboxamidas
CA2665931C (en) Hydrobenzamide derivatives as inhibitors of hsp90
AR051754A1 (es) Metodos para preparar compuestos de indazol
EA201201496A1 (ru) Способ ингибирования интегразы вич, способ улучшения фармакокинетики 6-(3-хлор-2-фторбензил)-1-[(2s)-1-гидрокси-3-метилбутан-2-ил]-7-метокси-4-оксо-1,4-дигидрохинолин-3-карбоновой кислоты (варианты), набор, фармацевтическая композиция (варианты) и антиретровирусный агент (варианты)
EA200901563A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
EA200970449A1 (ru) Композиции ацетаминофена, обладающие сведенными к минимуму побочными эффектами, включая пониженную гепатотоксичность
EA201290659A1 (ru) Новая композиция ретигабина
DK1678162T3 (da) P-glycoprotein-inhibitor, fremgangsmåde til fremstilling heraf og farmaceutisk sammensætning omfattende denne
IL181155A0 (en) 3-arylthioindole-2-carboxamide derivatives and analogs thereof as inhibitors of casein kinase i?á
NO20082181L (no) Formuleringer av Fispemifen
WO2009011901A3 (en) Methods for promoting wakefulness
WO2007133476A3 (en) Competitive substrate inhibition to increase drug bioavailability
DE602005016711D1 (de) Isoxazolsäure-derivat zur linderung neuropathischer schmerzen
WO2010011686A3 (en) Amides as inhibitors of human secreted phospholipase a2
BRPI0510465A (pt) formulação de droga oral semi-sólida ou lìquida
EA200800281A1 (ru) Способ коррекции экспериментального миокардита с помощью мицеллярной формы интерферона альфа

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1713458

Country of ref document: EP